Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1177
- Registration Number
- NCT03524092
- Locations
- 🇺🇸
Physicians Research Group, Tempe, Arizona, United States
🇺🇸SIH Research, LLC, Kissimmee, Florida, United States
🇺🇸Care Access Research, Berkeley, California, United States
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1063
- Registration Number
- NCT03519945
- Locations
- 🇮🇹
Ospedale San Martino, Genova, Italy
🇮🇹Ospedale Mauriziano, Torino, Italy
🇯🇵National Hospital Organization Hirosaki National Hospital, Hirosaki, Aomori, Japan
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1281
- Registration Number
- NCT03518086
- Locations
- 🇺🇸
Gastroenterology Consultants of Clearwater, Clearwater, Florida, United States
🇺🇸Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States
🇮🇳Poona Medical Foundation. Ruby Hall Clinic, Pune, Maharashtra, India
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT03518073
- Locations
- 🇨🇦
Q&T Research Sherbrooke Inc., Sherbrooke, Quebec, Canada
🇺🇸Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Pharmacology Research Institute, Los Alamitos, California, United States
A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03506399
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
A Study of LY3314814 in Participants With Liver Impairment
- Conditions
- Hepatic Impairment
- Interventions
- Drug: LY3314814
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT03499041
- Locations
- 🇺🇸
New Orleans Cntr for Clin Res, Knoxville, Tennessee, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1842
- Registration Number
- NCT03495102
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Saltzer Medical Group. P.A., Nampa, Idaho, United States
A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT03482024
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸High Point Clinical Trials Center, High Point, North Carolina, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT03482011
- Locations
- 🇺🇸
The South Bend Clinic, South Bend, Indiana, United States
🇲🇽B&B Investigaciones Medicas, SC, Mazatlan, Sinaloa, Mexico
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT03465878
- Locations
- 🇨🇦
LMC Endocrinology Centres Ltd., Toronto, Ontario, Canada
🇩🇪Kinderkrankenhaus auf der Bult, Hannover, Niedersachsen, Germany